TUDOR INVESTMENT CORP ET AL - ESPERION THERAPEUTICS INC NE ownership

ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 155 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2024. The put-call ratio across all filers is 0.49 and the average weighting 0.1%.

Quarter-by-quarter ownership
TUDOR INVESTMENT CORP ET AL ownership history of ESPERION THERAPEUTICS INC NE
ValueSharesWeighting
Q1 2024$115,814
+62.9%
43,214
-40.4%
0.00%0.0%
Q3 2023$71,075
-29.5%
72,5250.0%0.00%0.0%
Q2 2023$100,810
+51863.9%
72,525
-40.5%
0.00%
-66.7%
Q1 2023$194
-63.3%
121,981
+43.6%
0.00%
-70.0%
Q4 2022$529
-99.9%
84,949
+18.9%
0.01%0.0%
Q3 2022$479,000
+64.0%
71,444
+55.7%
0.01%
+25.0%
Q2 2022$292,000
-13.4%
45,897
-36.7%
0.01%0.0%
Q1 2022$337,000
-6.9%
72,524
+0.2%
0.01%
+33.3%
Q4 2021$362,000
-57.4%
72,356
+2.5%
0.01%
-57.1%
Q3 2021$850,000
+37.1%
70,571
+140.6%
0.01%
+16.7%
Q2 2021$620,000
-24.7%
29,3340.0%0.01%
-29.4%
Q1 2021$823,000
-18.4%
29,334
-24.4%
0.02%
-39.3%
Q4 2020$1,008,000
+189.7%
38,780
+314.4%
0.03%
+86.7%
Q3 2020$348,000
-24.3%
9,359
-5.4%
0.02%
+15.4%
Q2 2019$460,000
+123.3%
9,890
+92.3%
0.01%
+44.4%
Q1 2019$206,000
-58.0%
5,143
-51.8%
0.01%
-10.0%
Q4 2018$491,000
-77.2%
10,674
-75.2%
0.01%
-81.8%
Q3 2017$2,153,000
+295.0%
42,954
+85.9%
0.06%
+205.6%
Q3 2015$545,000
-0.4%
23,100
+291.3%
0.02%0.0%
Q1 2015$547,000
+189.4%
5,903
-41.0%
0.02%
+125.0%
Q3 2013$189,00010,0000.01%
Other shareholders
ESPERION THERAPEUTICS INC NE shareholders Q1 2024
NameSharesValueWeighting ↓
Meditor Group Ltd 2,818,835$33,967,00011.67%
PLATINUM INVESTMENT MANAGEMENT LTD 1,713,176$20,644,0000.58%
Bellevue Group AG 4,519,164$54,455,0000.55%
Rhenman & Partners Asset Management AB 622,267$7,498,0000.53%
JACOB ASSET MANAGEMENT OF NEW YORK LLC 47,534$573,0000.21%
WASATCH ADVISORS LP 3,274,360$39,456,0000.16%
EMC Capital Management 27,566$246,0000.14%
PDT Partners, LLC 120,828$1,456,0000.10%
Virtus ETF Advisers LLC 17,773$214,0000.09%
Pinz Capital Management, LP 15,300$184,0000.08%
View complete list of ESPERION THERAPEUTICS INC NE shareholders